Abstract: A method of making a semiconductor structure includes forming a first conductive line and a second conductive line in a first dielectric layer. The method further includes recessing the first conductive line, wherein a thickness of the second conductive line is greater than the recessed first conductive line. The method further includes forming a third conductive line in a second dielectric layer overlying the first dielectric layer, wherein the third conductive line extends above at least the second conductive line. Forming the third conductive line includes forming a via in the second dielectric layer and electrically connecting the second conductive line and the third conductive line, wherein a first portion of the via lands on a portion of the second conductive line, and a second portion of the via extends between the first conductive line and the second conductive line.

Abstract: A method of forming patterns includes at least the following steps. A first dielectric layer having a first opening is provided. A first seed layer and a first conductive layer are deposited in the first opening. A portion of the first conductive layer is removed to form a recess. A vacancy migration blocking layer and a second conductive layer are deposited in the recess such that the first seed layer, the first conductive layer, the vacancy migration blocking layer, and the second conductive layer form a first pattern.

Abstract: The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.

Abstract: A protecting method for preventing solder crack failure in an electronic product is provided. Firstly, a step (a) is performed to confirm that a crack incidence rate of a metallic solder material in a printed circuit board is high. In a step (b), a protecting mechanism of controlling the electronic product to enter an idle mode and leave the idle mode is activated. Consequently, an operating temperature of the electronic product decreases at a first average drop rate.

Abstract: The disclosure features isolated mRNAs encoding a polypeptide that enhances immune responses to an antigen(s) of interest, such as polypeptides that activate Type I interferon pathway signaling or NFkB signaling, including mRNAs comprising one or more modified nucleobase. The disclosure also features methods of using the same, for example, for enhancing immune responses when administered with an antigen(s) of interest, such as to stimulate anti-cancer immune responses or anti-pathogen immune responses.

Abstract: The invention relates to concatemeric peptide epitope RNAs, as well as methods and compositions thereof. mRNA vaccines are also provided according to the invention, including cancer vaccines.

Abstract: The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.

Abstract: A method of forming a semiconductor structure includes forming a plurality of lower level conductive lines in a first dielectric layer. The plurality of lower level conductive lines includes a first lower level conductive line. The method further includes recessing portions of the first lower level conductive line below a top surface of the first dielectric layer to form a recess, forming a dielectric cap in the recess, depositing a second dielectric layer over the first dielectric layer. Forming a via opening exposes a portion of the second lower level conductive line. The method further includes forming an upper level conductive line and a via in the trench and in the via opening, respectively. The via couples the upper level conductive line to the second lower level conductive line, and the upper level conductive line overlaps with the dielectric cap.

Abstract: A connecting assembly for aligning and connecting a first electronic device and a second electronic device is provided. The connecting assembly includes a first connecting component, a second connecting component, a pin, a resilient component and a locking component. The first connecting component is disposed on the first electronic device. The second connecting component is disposed on the second electronic device. The pin protrudes from the first connecting component and is configured to be inserted into the second connecting component along a first direction. The resilient component is disposed inside the second connecting component and configured to apply a radial resilient force onto the pin inserted into the second connecting component. The locking component is screwed onto the second connecting component and configured to apply a radial locking force onto the pin inserted into the second connecting component. Besides, a related electronic apparatus is also provided.

Abstract: A connecting assembly for providing an aligning connection between a first electronic device and a second electronic device includes a first connecting component disposed on the first electronic device, a plurality of first heat dissipating fins disposed on the first connecting component, a second connecting component disposed on the second electronic device, a plurality of second heat dissipating fins disposed on the second connecting component, and a pin. An engaging portion is formed on one of the first heat dissipating fins. A cooperating engaging portion is formed on one of the second heat dissipating fins. The pin protrudes from the first connecting component and for being inserted into the second connecting component. The engaging portion is for abutting against the cooperating engaging portion along a direction perpendicular to an inserting direction of the pin. Besides, a related electronic apparatus is also provided.

Abstract: The disclosure features lipid nanoparticle (LNP) compositions ITB6 molecules and uses thereof. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding ITB6 polypeptides. The LNP compositions of the present disclosure can reprogram dendritic cells, suppress T cells and/or induce immune tolerance in vivo.

Abstract: The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.

Abstract: The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (NAVs) comprising polynucleotide molecules encoding one or more antigens.

Abstract: The disclosure features lipid nanoparticle (LNP) compositions comprising metabolic reprogramming molecules and membrane anchoring moieties and uses thereof. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding metabolic reprogramming polypeptides, e.g., IDO or TDO and membrane anchoring moieties. The LNP compositions of the present disclosure can reprogram myeloid and/or dendritic cells, suppress T cells and/or induce immune tolerance in vivo.

Abstract: The invention relates to compositions and methods for the preparation, manufacture, and therapeutic use of ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more antigens.

Abstract: The invention relates to concatemeric peptide epitope RNAs, as well as methods and compositions thereof. mRNA vaccines are also provided according to the invention, including cancer vaccines.

Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.

Abstract: The disclosure features lipid nanoparticle (LNP) compositions comprising immune modulating polypeptides and uses thereof. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding immune modulating polypeptides, e.g., interleukin 2 (IL-2) and/or granulocyte macrophage colony stimulating factor (GM-CSF). The LNP compositions of the present disclosure can stimulate T regulatory cells, e.g., increase the level and/or activity of T regulatory cells in vivo or ex vivo.

Abstract: The disclosure features lipid nanoparticle (LNP) compositions comprising mRNA molecules encoding human granulocyte macrophage colony stimulating factor (GM-CSF) polypeptides and uses thereof in the treatment of Parkinson's Disease. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding human GM-CSF for use in such treatment.